| | |
Page
|
| |||
招股説明書副刊 | | | | | | | |
關於本招股説明書副刊
|
| | | | S-ii | | |
Market and Industry Data
|
| | | | S-iii | | |
Summary
|
| | | | S-1 | | |
Risk Factors
|
| | | | S-8 | | |
有關前瞻性陳述的特別説明
|
| | | | S-10 | | |
Use of Proceeds
|
| | | | S-12 | | |
Dilution
|
| | | | S-13 | | |
美國聯邦所得税和遺產税對非美國普通股持有者的重大影響
|
| | | | S-15 | | |
Underwriting
|
| | | | S-18 | | |
Legal Matters
|
| | | | S-29 | | |
Experts
|
| | | | S-29 | | |
您可以在哪裏找到更多信息
|
| | | | S-29 | | |
引用註冊成立
|
| | | | S-30 | | |
| PROSPECTUS | | | |||||
|
About This Prospectus
|
| | | | 1 | | |
|
您可以在哪裏找到更多信息
|
| | | | 2 | | |
|
引用註冊成立
|
| | | | 3 | | |
|
The Company
|
| | | | 4 | | |
|
Risk Factors
|
| | | | 5 | | |
|
有關前瞻性陳述的特別説明
|
| | | | 6 | | |
|
Use of Proceeds
|
| | | | 8 | | |
|
股本説明
|
| | | | 9 | | |
|
債務證券説明
|
| | | | 13 | | |
|
認股權證説明
|
| | | | 21 | | |
|
Description of Rights
|
| | | | 23 | | |
|
備貨合同説明
|
| | | | 24 | | |
|
Description of Units
|
| | | | 25 | | |
|
Plan of Distribution
|
| | | | 26 | | |
|
Legal Matters
|
| | | | 27 | | |
|
Experts
|
| | | | 27 | | |
| | |
Dose Level 1
1 x 1011 vp (N=3) |
| |
Dose Level 2
5 x 1011 vp (N=12) |
| |
All Subjects (N=15)
|
| |||||||||
| | |
Subjects
(N, %) |
| |
Events
(N) |
| |
Subjects
(N, %) |
| |
Events
(N) |
| |
Subjects
(N, %) |
| |
Events
(N) |
|
Grade 1
|
| |
3 (100%)
|
| |
7
|
| |
12 (100%)
|
| |
105
|
| |
15 (100%)
|
| |
112
|
|
Grade 2
|
| |
0 (0%)
|
| |
0
|
| |
2 (16.7%)
|
| |
4
|
| |
2 (13.3%)
|
| |
4
|
|
Grades 3 – 5
|
| |
0 (0%)
|
| |
0
|
| |
0 (0%)
|
| |
0
|
| |
0 (0%)
|
| |
0
|
|
| | |
Grade 1
|
| |
Grade 2
|
| ||||||
| | |
Subjects
(N, %) |
| |
Events
(N) |
| |
Subjects
(N, %) |
| |
Events
(N) |
|
Chills
|
| |
10/15
(66.7%) |
| |
14
|
| |
0 (0%)
|
| |
0
|
|
Diarrhea
|
| |
1/15
(6.7%) |
| |
1
|
| |
0 (0%)
|
| |
0
|
|
Shortness of breath (Dyspnea)
|
| |
1/15
(6.7%) |
| |
1
|
| |
0 (0%)
|
| |
0
|
|
多汗(多汗症)
|
| |
2/15
(13.3%) |
| |
2
|
| |
0 (0%)
|
| |
0
|
|
Fatigue
|
| |
9/15
(60.0%) |
| |
20
|
| |
2/15
(13.3%) |
| |
2
|
|
Fever
|
| |
9/15
(60.0%) |
| |
17
|
| |
0 (0%)
|
| |
0
|
|
| | |
Grade 1
|
| |
Grade 2
|
| ||||||
| | |
Subjects
(N, %) |
| |
Events
(N) |
| |
Subjects
(N, %) |
| |
Events
(N) |
|
Injection site reaction
|
| |
15/15
(100%) |
| |
46
|
| |
0 (0%)
|
| |
0
|
|
Muscle aches (Myalgia)
|
| |
2/15
(13.3%) |
| |
2
|
| |
2/15
(13.3%) |
| |
2
|
|
Nausea
|
| |
4/15
(26.7%) |
| |
6
|
| |
0 (0%)
|
| |
0
|
|
Skin itching (Pruritus)
|
| |
1/15
(6.7%) |
| |
1
|
| |
0 (0%)
|
| |
0
|
|
Vomiting
|
| |
2/15
(13.3%) |
| |
2
|
| |
0 (0%)
|
| |
0
|
|
| | |
Dose Level 1
(N=3) |
| |
Dose Level 2
(N=12) |
|
Complete Response (CR)
治療後12個月內不需要手術 |
| |
0% (0/3)
|
| |
50% (6/12)
|
|
Overall Response Rate (ORR)
與治療前12個月相比,治療後12個月的≥減少了50% |
| |
33% (1/3)
|
| |
58% (7/12)
|
|
Decrease in Rate of Surgery
治療後12個月與治療前12個月的比較 |
| |
100% (3/3)
|
| |
83% (10/12)
|
|
|
每股公開發行價
|
| | | | | | | | | $ | | | |
|
截至2022年9月30日的每股有形賬面淨值(虧損)
|
| | | $ | 0.30 | | | | | | | | |
|
本次發售中可歸因於購買者的每股有形賬面淨值增加
|
| | | $ | | | | | | | | | |
|
緊接本次發行後的調整後每股有形賬面淨值
|
| | | | | | | | | $ | | | |
|
本次發售中對購買者的每股攤薄
|
| | | | | | | | | $ | | | |
Name
|
| |
Number of Shares
|
|
J.P. Morgan Securities LLC
|
| | | |
Cantor Fitzgerald & Co.
|
| | | |
JMP Securities LLC
|
| | | |
Total
|
| | | |
|
| | |
Without
option to purchase additional shares exercise |
| |
With full
option to purchase additional shares exercise |
| ||||||
Per Share
|
| | | $ | | | | | $ | | | ||
Total
|
| | | $ | | | | | $ | | | |
|
About This Prospectus
|
| | | | 1 | | |
|
您可以在哪裏找到更多信息
|
| | | | 2 | | |
|
引用註冊成立
|
| | | | 3 | | |
|
The Company
|
| | | | 4 | | |
|
Risk Factors
|
| | | | 5 | | |
|
有關前瞻性陳述的特別説明
|
| | | | 6 | | |
|
Use of Proceeds
|
| | | | 8 | | |
|
股本説明
|
| | | | 9 | | |
|
債務證券説明
|
| | | | 13 | | |
|
認股權證説明
|
| | | | 21 | | |
|
Description of Rights
|
| | | | 23 | | |
|
備貨合同説明
|
| | | | 24 | | |
|
Description of Units
|
| | | | 25 | | |
|
Plan of Distribution
|
| | | | 26 | | |
|
Legal Matters
|
| | | | 27 | | |
|
Experts
|
| | | | 27 | | |
| J.P. Morgan | | |
Cantor
|
|